IL-28B polymorphisms and treatment response in hepatitis C virus patients with persistently normal alanine aminotransferase

doi:10.4254/wjh.v5.i11.635

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 5, Issue 11

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4718)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

242

HTML

2416

Figures (1-1)

219

Tables (1-4)

230

Sum=3107

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

853

Download

758

Sum=1611

Nov 27, 2013 (publication date) through Nov 25, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Hepatol. Nov 27, 2013; 5(11): 635-641
Published online Nov 27, 2013. doi: 10.4254/wjh.v5.i11.635

Table 1 Patient baseline and demographic characteristics, and treatment response in the present study

	Total	PNALT	Abnormal ALT	P value
Number of patients	278	100	178
Age (yr)	55.6 ± 11.4	56.2 ± 10.9	55.3 ± 11.6	0.526
Gender (male/female)	136/142	31/69	105/73	< 0.0001
AST (IU/L)	56.6 ± 44.7	29.8 ± 12.1	71.3 ± 49.1	< 0.0001
ALT (IU/L)	70.5 ± 64.3	27.6 ± 7.2	94.6 ± 69.4	< 0.0001
γ-GT (IU/L)	50.7 ± 57.3	26.2 ± 22.1	64.1 ± 65.7	< 0.0001
WBC (/mm³)	5190 ± 1500	5060 ± 1490	5260 ± 1510	0.28
Hemoglobin (g/dL)	14.4 ± 7.1	13.5 ± 1.2	15.0 ± 8.9	0.094
Platelets (× 10⁴/mm³)	17.1 ± 5.6	17.7 ± 5.9	16.8 ± 5.5	0.20
Previous treatment (-/+)	211/67	75/25	136/42	0.90
IL-28B SNP(Maj/Min)	189/89	70/30	119/59	0.68
VR/Null response	203/65	84/16	129/49	0.042
RVR (+/-)	32/200	12/70	20/130	0.93
EVR (+/-)	116/118	46/36	70/82	0.18
SVR (+/-)	143/135	56/44	87/91	0.30

Data are expressed as the mean ± SD. P values are for comparisons between the persistent normal alanine aminotransferase (PNALT)- and abnormal alanine aminotransferase (ALT)-groups by Student’s t-test or χ² test. AST: Aspartate aminotransferase; γ-GT: Gamma-glutamyl transpeptidase; WBC: White blood cell count; IL-28B: Interleukin 28B; SNP: single-nucleotide polymorphisms; Maj: Major genotype; Min: Minor genotype; VR: Virologic response; RVR: Rapid virologic response; EVR: Early virologic response; SVR: Sustained virologic response.

Citation: Miyamura T, Kanda T, Nakamura M, Jiang X, Wu S, Nakamoto S, Mikami S, Takada N, Imazeki F, Yokosuka O. IL-28B polymorphisms and treatment response in hepatitis C virus patients with persistently normal alanine aminotransferase. World J Hepatol 2013; 5(11): 635-641
URL: https://www.wjgnet.com/1948-5182/full/v5/i11/635.htm
DOI: https://dx.doi.org/10.4254/wjh.v5.i11.635